Editorial
Split Viewer
Korean J Hematol 2011; 46(4):
Published online December 31, 2011
https://doi.org/10.5045/kjh.2011.46.4.209
© The Korean Society of Hematology
CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
Division of Hematology/Oncology, Department of Internal Medicine, School of Medicine, Chungnam National University, Daejeon, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Larochelle, A, Krouse, A, Metzger, M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood, 2006;107;3772-3778.
- Vose, JM, Ho, AD, Coiffier, B, et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma, 2009;50;1412-1421.
- DiPersio, JF, Micallef, IN, Stiff, PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol, 2009;27;4767-4773.
- Laurence, AD. Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol, 2006;132;255-267.
- Zeng, Z, Shi, YX, Samudio, IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 2009;113;6215-6224.
- Tsutsumi, H, Tanaka, T, Ohashi, N, et al. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers, 2007;88;279-289.
- Juarez, J, Bradstock, KF, Gottlieb, DJ, Bendall, LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia, 2003;17;1294-1300.
- Tavor, S, Eisenbach, M, Jacob-Hirsch, J, et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia, 2008;22;2151-5158.
- Beider, K, Begin, M, Abraham, M, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol, 2011;39;282-292.
- Kim, HY, Hwang, JY, Oh, YS, et al. Differential effects of CXCR4 antagonists on the survival and proliferation on myeloid leukemia cells in vitro. Korean J Hematol, 2011;46;244-252.
PDF
Standard view
Export citation
Share Article
Editorial
Korean J Hematol 2011; 46(4): 209-210
Published online December 31, 2011 https://doi.org/10.5045/kjh.2011.46.4.209
Copyright © The Korean Society of Hematology.
CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
Deog-Yeon Jo, M.D. Ph.D.
Division of Hematology/Oncology, Department of Internal Medicine, School of Medicine, Chungnam National University, Daejeon, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Larochelle, A, Krouse, A, Metzger, M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood, 2006;107;3772-3778.
- Vose, JM, Ho, AD, Coiffier, B, et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma, 2009;50;1412-1421.
- DiPersio, JF, Micallef, IN, Stiff, PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol, 2009;27;4767-4773.
- Laurence, AD. Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol, 2006;132;255-267.
- Zeng, Z, Shi, YX, Samudio, IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 2009;113;6215-6224.
- Tsutsumi, H, Tanaka, T, Ohashi, N, et al. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers, 2007;88;279-289.
- Juarez, J, Bradstock, KF, Gottlieb, DJ, Bendall, LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia, 2003;17;1294-1300.
- Tavor, S, Eisenbach, M, Jacob-Hirsch, J, et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia, 2008;22;2151-5158.
- Beider, K, Begin, M, Abraham, M, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol, 2011;39;282-292.
- Kim, HY, Hwang, JY, Oh, YS, et al. Differential effects of CXCR4 antagonists on the survival and proliferation on myeloid leukemia cells in vitro. Korean J Hematol, 2011;46;244-252.
Previous Article
